Our findings present the first evidence that JAM-A overexpression and its cleavage by ADAM enzymes are associated with anti-HER2 drug resistance and with aggressive phenotypes in patients with HER2-positive breast cancer. This evidence concerns the gene F11R and breast carcinoma.